infection, and a variety of renal disorders could occur throughout the course of the disease. HIVassociated nephropathy (HIVAN) is the most common form of kidney disease resulting directly from HIV infection. The true prevalence of HIVAN among infected African children is unknown largely due to lack of surveillance and reporting. We thus aimed to determine the prevalence of HIVAN and associated factors among HIV-infected children at the University of Maiduguri Teaching Hospital. This was a cross-sectional study carried out at the Pediatric Infectious Clinic. Children aged ≤15 years were recruited through systematic random sampling. Relevant sociodemographic and clinical information were obtained. Spot urine sample was analyzed using a multistix (Combi-Screen 10SL Analyticon Biotechnologies AG, Germany), and proteinuria of ≥2+ was considered significant. The CD4 + count and CD4 + % (for those <5 years) were obtained using a PARTEC™ CD4 + easy count kit. The obtained data were entered and analyzed using Statistical Package for the Social Sciences version 16.0. A total of 250 children were recruited. Eighty-five (34%) of them had HIVAN. Sex, social class, and mode of transmission were not significantly associated with HIVAN (P >0.05). However, age, medication status (highly active antiretroviral therapy [HAART]), duration on HAART, and disease severity (both clinical and immunological) all had a significant association to HIVAN (P = 0.005, 0.004, 0.008, and <0.001, respectively). These factors also showed a positive but weak correlation to HIVAN; while age had the least correlation coefficient (0.157), immunological class had the highest r = 0.458. However, these relationships were
Introduction
Human immunodeficiency virus (HIV) pandemic has remained an important public health issue globally with the sub-Saharan Africa subcontinent being the greatest hit. 1 Nigeria is known to have the largest number of HIV positive children in the world. 2 Prior to improved access to standard therapy of HIV disease, African children frequently died early from diarrhea-induced dehydration or respiratory infections. 3 However, with more patients having access to diagnosis and treatment with (highly active antiretroviral therapy [HAART] ), in addition to other supporting managements, there is a concomitant increase of survival of African children with HIV. Thus, HIV-infected children who would have succumbed to the disease now run a chronic course of the illness with long-term multisystem complications such as renal disease and cardiomyopathy. 4 The kidney is an important target organ in HIV infection, and a variety of renal disorders could occur through the course of the disease. 5 HIV-associated nephropathy (HIVAN), the most common form of kidney disease resulting directly from HIV infection, 6 is characterized by proteinuria, normal blood pressure (BP), elevated serum creatinine, normal to large echogenic kidneys on ultrasound imaging, and collapsing focal and segmental glomerulosclerosis on renal biopsy. 7 This disorder may relentlessly progress to end-stage renal disease within 8-16 weeks with mortality approaching 100% within six months of onset of uremia. 8 The mechanism underlying renal involvement in HIV-infected patients is still poorly understood, but both genetic factors [9] [10] [11] [12] and direct viral invasion [13] [14] [15] [16] are known to play significant roles in the pathogenesis of the disease. The true prevalence of HIVAN among infected African children is unknown, largely due to lack of surveillance and reporting. 17 In Nigeria, Esezobor et al, 18 using the presence of proteinuria, reported a prevalence of 20.5% among HIV-infected children from Lagos, South West Nigeria, while Ikpeme et al 17 found a higher prevalence of 31.6% using a more sensitive microalbuminuria from Uyo, South South Nigeria. 19 A prevalence of 24% was reported from South Africa among 615 HIV infected children. Previous studies from the USA 20 and Asia 21 have reported a lower prevalence of 15% and 10.7%, respectively, using the presence of significant proteinuria. The higher prevalence from African studies may be partly due to race. The black race has been found in several studies to be an important risk factor for the development of HIVAN. [9] [10] [11] 22 HIVAN is the most widely recognized cause of proteinuria in HIV-infected African-American children. 20, 23 Proteinuria is believed to be the earliest and most consistent clinical finding for the diagnosis of HIVAN. 24 Renal ultrasound scan (USS) and renal biopsy are other means of diagnosing HIVAN, but both are more expensive and require more expertise. Biopsy in addition is quite invasive, and the desired structural changes might not be picked in early cases with both USS and biopsy. Hence, proteinuria remains the most feasible screening tool in a poor setting like ours. We thus undertook this study to determine the prevalence of HIVAN and associated factors among HIV-infected children receiving care at the University of Maiduguri Teaching Hospital, Nigeria.
Materials and Methods
This cross-sectional study was conducted over a period of eight months between February and October 2014 at the Pediatric Infectious Disease Clinic of the University of Maiduguri Teaching Hospital, Borno State, located in the northeastern region of Nigeria. The Infectious Disease Clinic runs twice a week, Tuesdays and Fridays, with an average patient load of 50-60 patients per week. The study population was HIV-infected children aged 15 years and below attending the Pediatric Infectious Disease Clinic of the University of Maiduguri Teaching Hospital. The minimum sample size was determined using Taylor's formula
. The prevalence of proteinuria was taken at 20.5% from a previous study. 18 The calculated minimum sample size was 250 participants. The participants were selected using systematic random sampling. The sampling interval "K = 4" was determined by dividing total number of registered HIV-positive children (n = 1012) by the minimum sample size (n = 250). On each clinic day, patients were numbered as they registered; the first participant was selected by simple balloting of the first four participants to register and subsequently every 4 th participant. In case of noneligibility, the next patient who fulfilled the eligibility criteria was selected. Age of ≤15 years with verifiable positive HIV test result defined as two positive DNA polymerase chain reaction for those aged <18 months and two positive antibody test for those aged >18 months were eligible. Those with sickle cell anemia or hepatitis B and C virus infections or whose parents declined consent were excluded. The study protocol was reviewed and approved by the Research and Ethics Committee of our institution. A signed informed consent form was obtained from the parents/caregivers after passing adequate information regarding the research. Each parent/caregiver had unlimited liberty to decline without any consequence. The research material and information obtained were treated with utmost confidentiality; the result of the urinalysis was discussed with parents, and those with proteinuria or other abnormal findings were referred to the pediatric nephrology unit for further evaluation.
Study procedure
On the day of enrollment, information on biodata, sociodemographic features, detailed clinical features, and anthropometric measurements were obtained and recorded in a structured questionnaire. Information obtained included patient age, sex, parents' educational attainment, and occupation. Others included age at diagnosis, mode of transmission, duration on HAART, and the HAART regimen and clinical features at enrollment such as fever, skin rashes, cough, wasting, ear discharge, oral thrush, lymphadenopathy, difficulty in breathing, pallor, facial puffiness, and edema. The weight and height were measured to the nearest 0.05 kg and 0.5 cm, respectively, using Wunder's stadiometer fitted with a weighing scale. The weighing scale was adjusted to zero reading before each weighing, and a standard weight of 10 kg was used every day to recalibrate the scale. The height was measured with the child standing erect, and the head was positioned such that the Frankfurt plane was horizontal. Arms were hanging loosely at the side with palms facing the thigh. The movable headboard was then gently lowered until it could touch the crown of the head. The height measurement was taken with the examiner's eyes leveled with the headboard to avoid parallax error. For younger children or very ill ones who could not stand erect, a measuring board was used with the help of an assistant. Socioeconomic status of the children was determined from the parents' educational attainment and occupation using Oyedeji's model. 26 BP (mm Hg) was measured using Accuson's mercury sphygmomanometer with appropriate cuffs. Systolic and diastolic BP was indicated by the 1 st and 5 th Korotkoff sounds, respectively. 27 Two measurements were taken and the average of the two was recorded as the BP. BP was categorized using appropriate nomogram for age, sex, and height, into normal, high, or low. 28 The clinical features and anthropometry were used in staging the patients as per the World Health Organization (WHO) clinical staging for infants and children. 29 The WHO clinical Stages 1 and 2 were defined as nonadvanced disease, while Stages 3 and 4 were advanced disease. Age categorization was based on the WHO immunological classification of HIV infection in children. 29 
Laboratory procedures
On the day of recruitment into the study, 2.5 mL of venous blood was collected using aseptic technique into ethylenediaminetetraacetic acid (EDTA) bottle for hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (HCVAb) screening as well as CD4 + count and CD4 + % enumeration.
Hepatitis B surface antigen and hepatitis C virus antibody screening
Screening for HBsAg and HCVAb was carried out using micropoint HBsAg and HCVAb gold rapid screen test for the qualitative detection of the viruses. A drop of blood was added onto the sample pad strip. After the blood was completely absorbed, a drop of whole blood diluent was added. Results were read in 5-20 min as per manufacturer's instructions. Patients found to be positive for either HBsAg or HCVAb were excluded from further analysis and the study.
CD4
+ count and CD4 + percentage estimation The CD4 + count and CD4 + % (for children <5 years) were obtained using a PARTEC™ CD4 + easy count kit. Twenty microliters (µL) of blood (EDTA as anticoagulant) was dropped into a PARTEC™ easy count test tube using pipette. Twenty µL of CD4+ mouse antibody (mAb) PE was added to the blood and gently mixed and allowed to incubate for 15 min at room temperature. Eight hundred µL of no lyse buffer was added and mixed thoroughly. The mixed sample was analyzed on a PARTEC™ (GmbH Gőrlitz Germany) flow cytometer, with an excitation light source of 488 nM or 532 nM. Enumeration of CD4 + count and percentage was done as per manufacturer's instruction in the presence of the investigator. Using the WHO age-related CD4 count and CD4% values, the children were stratified into four groups: no significant immunosuppression, mild immunosuppression, advanced immunosuppression, and severe immunosuppression. 29 However, for this study, both no significant and mild immunosuppression were grouped as nonsevere immunosuppression, while both advanced and severe suppression were grouped together as severe immunosuppression.
Urine analysis
Spot urine sample was collected in a universal bottle. The urine was analyzed by the investigator using a multistix (Combi-screen 10SL Analyticon Biotechnologies AG, Germany). The test strip was immersed into the freshly voided urine for approximately 2-3 s, making sure that all the color pads on the strip were completely immersed in the urine as recommended by the manufacturers. It was drawn across the rim of the container to remove excess urine. It was then read after 60 s to allow reaction of embedded chemicals with urine for semi-quantitative analysis as appropriate. This was done under optimum light conditions by aligning the strip to the standard color-coded guide. Proteinuria which was more specific to albumin on dipstick was reported as negative, 1+ (30 mg/dL), 2+ (100 mg/dL), 3+ (300 mg/ dL), or 4+ (1000 mg/dL). Significant proteinuria (defined as the presence of 2+ or more of protein in urine), 30 urine specific gravity, glucose, blood, pH, and nitrite were checked. All urine samples were analyzed within 2 h of collection as recommended by the manufacturer.
Statistical Analysis
The data were collected, entered, and cleaned in a computer. Analysis was done using Statistical Package for the Social Sciences (SPSS) version 16.0 (SPSS, Chicago, IL, USA). Values were expressed as mean ± standard deviation (mean ± SD). Both numerical and categorical variables were generated. Student's t-test was used to test differences between means of continuous variable, and Chi-square and Fisher's exact tests were used where applicable for categorical variables. Correlation between immunological status (CD4 + count and CD4 + %), WHO clinical stage, and HIVAN were performed using Spearman's rank correlation. Logistic regression was performed to assess the relationship between study variables and HIVAN. P <0.05 was considered significant. Tables and Figure were used for illustrations as appropriate.
Results
A total of 250 patients were recruited for the study. The children were aged between five months and 180 months, with a mean ± SD age of 89.02 ± 47.95 months. Majority [163 (65.2%)] were aged ≥60 months, and infants were the least in number 18 (7.2%). There were 116 (46.4%) males and 134 (53.6%) females, with a male-to-female ratio (M:F) of approximately 1:1.1. One hundred and thirty-seven (54.8%) were of low social class, while 40 (16.0%) were of upper social class (Table 1) .
Treatment modalities, mode of disease transmission, and clinical and immunological disease severity are shown in Table 2 . One hundred and fifty-seven children (62.8%) were on HAART for a period ranging from 1 to 168 months, with a mean duration of 66.06 ± 46.47 months. One hundred and forty-three children (91.1%) on HAART were on a regimen consisting of zidovudine, lamivudine, and nevirapine. The remaining 14 patients (8.9%) were on other regimens including either abacavir or efavirenz in place of nevirapine. Twenty of the 250 participants (8%) were on antituberculous treatment; of these, six were on HAART. Majority of the study population [231 (92.4%)] acquired the infection through vertical transmission. Mode of transmission could not be ascertained in 14 patients who were mostly adolescents. A total of 93 participants (37.2%) had advanced disease comprising WHO clinical Stages 3 and 4. One hundred and three (41.2%) had advanced or severe immunosuppression. A total of 85 (34%) of the study population had HIVAN based on significant proteinuria ≥2+; of these, 27 (31.8%) had nephrotic-range proteinuria ≥3+ (Figure 1) . Among the group with proteinuria, 67 participants (78.8%) were aged ≥60 months, 51 (60%) were of low socioeconomic class, 50 (58.8%) had advanced HIV disease, and 63 (74.1%) had severe immunosuppression, while 57 (67.1%) were either HAART naive or <1 year on HAART. Gender, social class, and mode of transmission were not significantly associated with significant proteinuria (P >0.05). However, age, medication (HAART) status, duration on HAART, and disease severity (both clinical and immunological) were significantly associated with significant proteinuria (P = 0.005, 0.004, 0.008, and <0.001, respectively; Table 3 ). The mean ± SD systolic and diastolic BP among those with significant proteinuria was 103.06 ± 13.00 and 61.71 ± 9.49, respectively. Children without significant proteinuria had mean ± SD systolic and diastolic BP of 95.30 ± 11.66 and 57.30 ± 8.84, respectively. Although the mean ± SD BP of both groups were within normal limits, those with significant proteinuria had significantly higher BP, t = −4.79 and −3.64 for systolic and diastolic BP, respectively; P <0.001 in both. Table 4 shows the strength and direction of relationship between HIVAN and some of the factors with a significant association. All the factors showed a positive but weak correlation to HIVAN, while age had the least correlation coefficient (0.157) and immunological class had the highest r = 0.458. However, these relationships were all significant (P <0.5). The effect of various factors on the prevalence of HIVAN is depicted in the binary logistic regression in Table 5 . While infants were 0.5 times less likely to have HIVAN, children aged 13-59 months were 1.2 times more likely when compared to those aged ≥60 months. These effects of age were, however, not significant; P values are 0.555 and 0.709, respectively. Similarly, sex and social class had no significant effect on the prevalence of HIVAN. In contrast, children who were on HAART had nonsevere immunosuppression and nonadvanced clinical diseases and were less likely to have HIVAN when compared to those who were not on HAART, who had severe immunosuppression and advanced disease.
Discussion
The prevalence of 34.0% for HIVAN recorded in this study is quite high underscoring the need for routine screening of all HIV-positive children. It is similar to the findings of Ikpeme et al 17 from Uyo but higher than that reported in the studies by Esezobor et al 18 from Lagos and Iduoriyekemwen et al 31 from Benin. The difference between the finding of the present study and that from Lagos 18 may be due to the differences in the definition of proteinuria. While proteinuria of 2+ on dipstick was considered significant proteinuria in this study, the Lagos study used urine protein-creatinine ratio which is more specific than dipstick in diagnosing Figure 1 . Prevalence of proteinuria among the study population. renal disorder. 32 In addition, more than onethird of the study population had advanced HIV/AIDS disease, and it has been demonstrated in this study and others 7, 17, 18, 20, 23, 33 that HIVAN occurs in a setting of severe immunosuppression. The lower prevalence reported by Benin 31 could be because all the studied patients were on HAART with relatively higher CD4 count compared to this study where 57 (67.1%) of those with significant proteinuria were either HAART naive or recently commenced therapy. Similarly, the lower prevalence documented by Strauss et al 23 and Ray et al 20 from America may be due to the racial differences between this study and theirs. It is known that black race is an important risk factor for HIVAN, 7 which constitutes 100% of the present study population. The American studies included both blacks and Caucasians.
Similar to previous studies, 17, 18, 34, 35 age had a significant association and positive correlation to HIVAN. The reason for this predilection could be because older children have supposedly longer duration of exposure to HIV. The natural course of HIV infection is such that with increasing duration of exposure, there is disease progression. 36 Although advanced disease and older age were significantly associated with a higher prevalence of HIVAN in this study, people living with HIV may present with HIVAN before developing other symptoms of AIDS or even during acute seroconversion illness. 37 This was corroborated in this study as age failed to demonstrate a significant effect on logistic regression. This is in conformity with the findings of Anochie et al 35 where duration from HIV infection to development of HIVAN ranged from five months to 10 years, and renal disease was the first manifestation of HIV infection in 60% of patients with HIVAN. It is possible that acquisition of HIV at a time when the kidneys are still developing may predispose to renal disease earlier in children compared to adults. 31 There was a significantly lower prevalence of HIVAN among patients using HAART. In addition, the prevalence further reduced with increasing duration of HAART use. This finding, however, is in contrast to that reported by Ikpeme et al 17 and Esezobor et al 18 who did not find any significant relationship between HAART use and prevalence of HIVAN. This difference may not be unconnected to the fact that the median duration of HAART use in this study was much higher than the Lagos and Uyo studies. 17, 18 Similar to our findings, other authors 15, 38 have reported a significant remission in renal disease by both clinical and histopathological criteria following commencement on HAART. It is known that the use of HAART over time suppresses viral load 39 and direct viral inversion of the kidney plays an important role in the pathogenesis of HIVAN. [13] [14] [15] [16] Hence, suppression of viral load may explain the pattern observed among those on HAART in this study. The mean systolic and diastolic BP was within normal limit for age, sex, and height in patients with HIVAN in this study. This is in tandem with findings of other studies that hypertension is not a feature of HIVAN. 17, 40 BP in HIVAN has been described as normal, and if raised, it is recommended that other causes of hypertension including other nephropathies should be excluded. 17, 40 This finding is thought to result from the propensity of the kidneys in HIVAN to lose salt and water. 20, 40 The observed higher mean BP among those with HIVAN in comparison to those without significant proteinuria may be due to the significantly higher age of those with HIVAN demonstrated in this study.
Conclusion
HIVAN is highly prevalent among children living with HIV in Maiduguri. Routine screening of all HIV-positive children using dipstick and early initiation of therapy with HAART would go a long way in reducing the burden of renal disease among these children.
